HER2-Positive Breast Cancer

Patients with HER2-positive breast cancer who were treated with trastuzumab deruxtecan experienced favorable activity and reduction or loss of HER2 expression.

A review of the currently available frontline treatment options for HER2+ breast cancer.

Virginia Kaklamani, MD, DSc, provides an overview of the goals of care for HER2+ breast cancer.

Fam-trastuzumab deruxtecan-nxki, which was granted a priority review designation, appears to have potential for patients with HER2-positive unresectable/metastatic breast cancer.

Research suggests a new HER2DX assay is potentially able to accurately predict risk of recurrence for patients with early-stage HER2-positive breast cancer.

Experts provide clinical pearls to the audience on treating patients with breast cancer.

The panelists share their insights on managing toxicities and special considerations in the treatment of HER2+ breast cancer.

Experts discussed the changing landscape in treatments for HER2-positive metastatic breast cancer.

Patient data from 4 clinical trials suggests HER2-low–positive tumors can be seen as a new breast cancer subgroup, specifically distinct from HER2-zero tumors.

Patient Case 2 is presented, and Dr Gadi and Dr Mahtani detail how they would proceed with treating this patient.

Patient Case 1 is presented to the panel, and Vijayakrishna Gadi, MD, PhD, shares his thoughts on how to approach treatment of this patient.

Reshma Mahtani, DO, discusses considerations for use of trastuzumab duocarmazine in HER2+ breast cancer.

Our panel of experts review the latest data on the antibody drug conjugate, trastuzumab duocarmazine.

Reshma Mahtani, DO, and Neil Iyengar, MD, discuss the data presented at ESMO 2021 in the TUXEDO-1 and HER2CLIMB-04 trials.

The panel analyzes the data from DESTINY-Breast03 and DESTINY-Breast01 and how these data will further impact practice.

Second-line fam-trastuzumab deruxtecan-nxki prolonged survival and led to higher responses over ado-trastuzumab emtansine for patients with HER2-positive metastatic breast cancer.

Patients with HER2-positive breast cancer appeared to derive a higher overall survival benefit after being treated with pyrotinib plus capecitabine vs lapatinib plus capecitabine.

Utilizing neratinib or abo-trastuzumab emtansine for patients with HER2-positive early stage breast cancer reduced the risk of distant recurrence.

The combination of trastuzumab deruxtecan and pertuzumab could improve efficacy over trastuzumab deruxtecan alone for patients with HER2-positive metastatic breast cancer.

Zanidatamab and single agent chemotherapy may hold promise in a population of patients with previously treated HER2-positive breast cancer.

Tucatinib plus palbociclib and letrozole prolonged central nervous system progression-free survival for patients with hormone receptor–positive, HER2-positive breast cancer.

Data collected from 1400 global laboratories indicate that standard immunohistochemistry testing may not be the most effective method to identify patients with breast cancer with HER2-low disease.

A study from the Yale Cancer Center potentially introduces a drug design platform to fight drug resistance for patients with HER2-positive breast cancer and ovarian cancer.

Experts discuss the use of trastuzumab-deruxtecan (T-DXd) in clinical practice.

Sara A. Hurvitz, MD, briefly describes the treatment landscape for HER2+ breast cancer and the panelists take an in-depth look at the data from the DESTINY-Breast03 trial.

For patients with HER2-positive metastatic breast cancer, CD8-positive, cytotoxic tumor infiltrating lymphocytes may be predictive of outcomes after treatment with trastuzumab.

“We’ve been spoiled by 2 extraordinary experiences [in this setting]. Both tucatinib and trastuzumab deruxtecan are much better than anything we’ve had since we got pertuzumab for first-line therapy.” —SARA A. HURVITZ, MD, FACP

Patients with invasive HE2-positive breast cancer who were treated with pegylated liposomal doxorubicin plus docetaxel and trastuzumab experienced an increase in a pathological complete response.

Patients receiving trastuzumab for HER2-positive breast cancer on the phase 3 HERA trial did not have an increased risk of cardiotoxicity from radiation therapy.

An interim analysis indicated that dalpiciclib plus pyrotinib yielded promising results in patients with HER2-positive advanced stage breast cancer.